| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Author Index > Browse Articles > Author Index

Author is indexed since 1999

Author :
Hoon-Gu Kim 7 Articles
Hematologic malignancy
304 Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)
Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won
Cancer Res Treat. 2023;55(1):304-313.   Published online March 30, 2022    DOI: https://doi.org/10.4143/crt.2022.004
                           Web of Science 1  Crossref 1
718 A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):718-726.   Published online September 3, 2018    DOI: https://doi.org/10.4143/crt.2018.324
                           Web of Science 10  Crossref 11
119 Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
Dong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, Keunchil Park, Hoon-Kyo Kim, Joung Soon Jang, Bong-Seog Kim, Jin-Hyoung Kang, Kyung Hee Lee, Sang-We Kim, Hun Mo Ryoo, Jin-Soo Kim, Ki Hyeong Lee, Jung Hye Kwon, Jin-Hyuk Choi, Sang Won Shin, Seokyung Hahn, Dae Seog Heo
Cancer Res Treat. 2019;51(1):119-127.   Published online March 12, 2018    DOI: https://doi.org/10.4143/crt.2018.019
                        Supplementary         Web of Science 24  Crossref 19
1252 Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park
Cancer Res Treat. 2018;50(4):1252-1259.   Published online January 2, 2018    DOI: https://doi.org/10.4143/crt.2017.438
                           Web of Science 28  Crossref 26
416 Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
Miso Kim, Bhumsuk Keam, Tae-Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong-Wan Kim, Hwan Jung Yun, Jong Seok Lee, Dae Seog Heo
Cancer Res Treat. 2017;49(2):416-422.   Published online July 28, 2016    DOI: https://doi.org/10.4143/crt.2016.121
                           Web of Science 27  Crossref 22
789 Population-Based Regional Cancer Incidence in Korea: Comparison between Urban and Rural Areas
Haa-Na Song, Se-Il Go, Won Sup Lee, Yire Kim, Hye Jung Choi, Un Seok Lee, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Yune Sik Kang, Jeong-Hee Lee, Jin-Myung Jung, Soon Chan Hong
Cancer Res Treat. 2016;48(2):789-797.   Published online July 14, 2015    DOI: https://doi.org/10.4143/crt.2015.062
                           Web of Science 22  Crossref 21
312 Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission
Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee
Cancer Res Treat. 2014;46(3):312-316.   Published online July 15, 2014    DOI: https://doi.org/10.4143/crt.2014.46.3.312
                           Web of Science 17  Crossref 15
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Journal Impact Factor 4.6
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
Metadata
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI